• Keine Ergebnisse gefunden

Supplementary Table S1 Map of the agnostically identified motif within breakpoint sequences

N/A
N/A
Protected

Academic year: 2022

Aktie "Supplementary Table S1 Map of the agnostically identified motif within breakpoint sequences"

Copied!
1
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

Supplementary Table S1 Map of the agnostically identified motif within breakpoint sequences

Patienta Strand BKP Distanceb Motifc p-value

P086-3 - +24 AATCTGCACCCACAGTGGTGTATTGGCA 8.13 x 10-6

P002-5 - +14 atatgtatatCACAGTGGatattaATAT 8.13 x 10-6

P069-3 + -7 GTGTGTTAAACAGAGTGGTATCCAAGTC 1.63 x 10-5

P068-3 + -8 GTGTGTTAAACAGAGTGGTATCCAAGTC 1.63 x 10-5

P068-5 - +6 ggtggtaattCACTGTGGGATGTACTAA 2.44 x 10-5

P003-5 - +28 ggtggtaattCACTGTGGgatgtactaa 2.44 x 10-5

P056-3 + -44 CCAGACACGGTGGCTCACGCCTG 3.77 x 10-5

P120-3 + -28 CACGTTCAAACACAATGGATACATGAAA 1.32 x 10-4

P003-3 - -10 taagaaccatCACAATGGgacctagagt 1.32 x 10-4

P034-3 + -31 CCCATGACTG

CAGGGAG

G GGCTGCCAGG 2.10 x 10-4

P147-5 - +23 aatgctgtgtCACAGAGAagacattcta 2.69 x 10-4

P056-5 + -8 CTTGCATCCTCAGAGAGAGAGAGAGAGA 3.16 x 10-4

P147-3 - -22 tttcttttagCACAATGAatttctgttc 4.81 x 10-4

P074-3 + -41 CACTTTATCAGACTGATATAATAATT 4.81 x 10-4

P074-5 - +11 tatggcattgCAGTGAGAtagGAACAAT 5.11 x 10-4

P086-5 - +33 gggggctgggCAGGGTTGagctgggtgt 6.43 x 10-4

P034-5 + -49 CACAGTTACTATGGAGTT 7.62 x 10-4

P121-3 + -2 AATGTGTGCACACTCCGGTGAGAAGCTC 7.93 x 10-4

P002-3 + 0 AATGTGTGCACACTCCGGTGAGAAGCTC 7.93 x 10-4

P069-5 - +12 gtgtgtgtgaCAGTGTGTataaTGCTGA 9.05 x 10-4

P121-5 - +30 ttatttggtaTAGTGTGGtataatggta 1.18 x 10-3

P120-5 + +21 AGCTATCCTTCAGAAATGAAGGAGAAAT 2.15 x 10-3

aMAST (Motif Alignment & Search Tool) search was performed using the left (-5) and right (-3) strand surrounding ±50 bp of each breakpoint.

bCalculation of the distance between motif start and breakpoint.

cWe highlight sequences that were maintained (uppercase) and lost (lowercase) after the fusion.

BKP, breakpoint.

Referenzen

ÄHNLICHE DOKUMENTE

[r]

Abbreviations: CDAI, Clinical Disease Activity Index; CI, confidence interval; CRP, C-reactive protein; csDMARDs, conventional synthetic disease-modifying antirheumatic

Supplementary

Frequency of distinct types of imaging tests performed during the first year after the first visit to the pediatric rheumatologist in patients with a complete year of observation

(((((((((((((((((((((rheumatoid) AND pannus)) OR (((rheumatoid) AND fibroblast) AND synovial)) OR ((rheumatoid) AND purpura)) OR ((rheumatoid) AND vasculitis)) OR ((rheumatoid)

bDMARD, biologic disease-modifying antirheumatic drug; COVID-19, the 2019 novel coronavirus

Kaplan-Meier plot demonstrating 6-month all-cause mortality by timing of cryptococcal antigen (CrAg) testing and outpatient/inpatient status at the time of HIV diagnosis among people

FTO CCAGAACCTGAGGAGAGAATGG CGATGTCTGTGAGGTCAAACGG ALKBH5 CCAGCTATGCTTCAGATCGCCT GGTTCTCTTCCTTGTCCATCTCC ALPL GCTGTAAGGACATCGCCTACCA CCTGGCTTTCTCGTCACTCTCA RUNX2